What is HC Wainwright's Forecast for ACRS FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Aclaris Therapeutics to a loss of $0.57 per share, from a projected loss of $0.61. It maintains a Buy rating and a $16 price target; the consensus EPS estimate is a loss of $0.59.
• Aclaris beat quarterly expectations, reporting a $0.12-per-share loss versus the $0.16 loss analysts expected, and revenue of $1.48 million versus a $1.27 million consensus.
• Analysts overall rate Aclaris a consensus Buy, with an average price target of $11.33. Shares opened at $4.15, down 2.1% in the article’s reported session.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - HC Wainwright lifted their FY2026 earnings estimates for shares of Aclaris Therapeutics in a research note issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.57) per share for the year, up from their prior forecast of ($0.61). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Aclaris Therapeutics' Q4 2026 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.51) EPS.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.04. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%.

A number of other brokerages also recently issued reports on ACRS. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research report on Wednesday, October 28th. Wedbush decreased their price objective on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 28th. Wall Street Zen raised shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Finally, Canaccord Genuity Group boosted their price target on shares of Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $11.33.

Aclaris Therapeutics Stock Down 2.1%

Aclaris Therapeutics stock opened at $4.15 on Wednesday. The stock has a market cap of $580.27 million, a price-to-earnings ratio of -7.16 and a beta of 0.96. The business has a 50-day simple moving average of $4.55 and a 200 day simple moving average of $4.53. Aclaris Therapeutics has a 52 week low of $2.10 and a 52 week high of $6.60.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Aclaris Therapeutics during the 2nd quarter valued at about $53,096,000. Rock Springs Capital Management LP boosted its stake in Aclaris Therapeutics by 0.4% in the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company's stock worth $16,772,000 after buying an additional 18,909 shares in the last quarter. Braidwell LP boosted its stake in Aclaris Therapeutics by 26.1% in the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company's stock worth $11,333,000 after buying an additional 443,232 shares in the last quarter. Palo Alto Investors LP bought a new position in Aclaris Therapeutics during the second quarter valued at approximately $8,535,045. Finally, Kalehua Capital Management LLC bought a new position in Aclaris Therapeutics during the first quarter valued at approximately $6,871,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company's development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.